{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:17:59Z","timestamp":1791865079219,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","award":["ORF-2026-74"],"award-info":[{"award-number":["ORF-2026-74"]}],"id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijid.2026.108485","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T23:35:49Z","timestamp":1771112149000},"page":"108485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Ceftazidime-avibactam versus ceftolozane-tazobactam in the treatment of drug-resistant Pseudomonas aeruginosa: a meta-analysis"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1508-8693","authenticated-orcid":false,"given":"Thamer A.","family":"Almangour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulaiman","family":"Alzunaydi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felwah","family":"AlManea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Alshahwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahd","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Ghonem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essam A.","family":"Tawfik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazed Saleh","family":"Alsowaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ijid.2026.108485_bib0001","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"issue":"Supplement_1","key":"10.1016\/j.ijid.2026.108485_bib0002","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/ofid\/ofy343","article-title":"Geographic and temporal patterns of Antimicrobial resistance in Pseudomonas aeruginosa over 20 years from the SENTRY Antimicrobial Surveillance Program, 1997\u20132016","volume":"6","author":"Shortridge","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2026.108485_bib0003","series-title":"Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance","article-title":"WHO bacterial priority pathogens List","year":"2024"},{"issue":"12","key":"10.1016\/j.ijid.2026.108485_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01858-17","article-title":"Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa isolates","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2026.108485_bib0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2017.06.007","article-title":"Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa","volume":"62","author":"Alatoom","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2026.108485_bib0006","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2147\/IDR.S350976","article-title":"Ceftazidime\/Avibactam versus Polymyxin B in the challenge of carbapenem-resistant Pseudomonas aeruginosa infection","volume":"15","author":"Chen","year":"2022","journal-title":"Infect Drug Resist"},{"issue":"2","key":"10.1016\/j.ijid.2026.108485_bib0007","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs Polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108485_bib0008","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jgar.2022.01.023","article-title":"Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study","volume":"28","author":"Almangour","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.ijid.2026.108485_bib0009","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/ph18010108","article-title":"Ceftazidime-avibactam versus colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter cohort study","volume":"18","author":"Almangour","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"15","key":"10.1016\/j.ijid.2026.108485_bib0010","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2026.108485_bib0011","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.ijid.2026.108485_bib0012","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.ijid.2026.108485_bib0013","unstructured":"Sterne JAC, Higgins JPT, and Reeves BC, on behalf of the development group for ACROBAT-NRSI. A Cochrane risk of bias assessment tool: for non-randomized studies of interventions (ACROBAT-NRSI), version 1.0.0, 24 September 2014. 2014 http:\/\/www.riskofbias.info [accessed March 2023]."},{"issue":"Supplement_2","key":"10.1016\/j.ijid.2026.108485_bib0014","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac492.115","article-title":"1649. Ceftolozane-Tazobactam or Ceftazidime-Avibactam versus best available therapy in the treatment of difficult-to-treat Pseudomonas aeruginosa infections: a retrospective comparative effectiveness analysis of 195 U.S. Hospitals, 2016\u20132020","volume":"9","author":"Lawandi","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.ijid.2026.108485_bib0015","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00405-23","article-title":"Ceftolozane-Tazobactam versus Ceftazidime-Avibactam for the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa: a multicenter cohort study","volume":"67","author":"Almangour","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ijid.2026.108485_bib0016","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S1473-3099(24)00648-0","article-title":"Effectiveness of ceftazidime-avibactam versus Ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study","volume":"25","author":"Shields","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.ijid.2026.108485_bib0017","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1093\/jac\/dkae313","article-title":"Comparative evaluation of early treatment with ceftolozane\/tazobactam versus ceftazidime\/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa","volume":"79","author":"Lodise","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.ijid.2026.108485_bib0018","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3390\/antibiotics13080699","article-title":"Clinical outcomes of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam in managing pseudomonal infections in patients undergoing renal replacement therapy","volume":"13","author":"El Nekidy","year":"2024","journal-title":"Antibiotics (Basel)"},{"issue":"10","key":"10.1016\/j.ijid.2026.108485_bib0019","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00907-24","article-title":"Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam","volume":"68","author":"Hareza","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"Supplement_2","key":"10.1016\/j.ijid.2026.108485_bib0020","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac492.1359","article-title":"1729. Real-world experience with Ceftazidime-avibactam compared with Ceftolozane-tazobactam on clinical outcomes in Pseudomonas aeruginosa infections","volume":"9","author":"Golia","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.ijid.2026.108485_bib0021","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/cid\/ciae332","article-title":"Rates of resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam among patients treated for multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia","volume":"80","author":"Shah","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108485_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1347521","article-title":"Extensively drug-resistant Pseudomonas aeruginosa: clinical features and treatment with ceftazidime\/avibactam and ceftolozane\/tazobactam in a tertiary care university hospital center in Portugal \u2013 a cross-sectional and retrospective observational study","volume":"15","author":"Mendes Pedro","year":"2024","journal-title":"Front Microbiol"},{"issue":"5","key":"10.1016\/j.ijid.2026.108485_bib0023","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/jac\/dkaf080","article-title":"Antipseudomonal cephalosporins versus piperacillin\/tazobactam or carbapenems for the definitive antibiotic treatment of Pseudomonas aeruginosa bacteraemia: new kids on the ICU block?","volume":"80","author":"Bavaro","year":"2025","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.ijid.2026.108485_bib0024","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s42770-023-01193-x","article-title":"Clinical outcomes of intensive care unit patients infected with multidrug-resistant gram-negative bacteria treated with ceftazidime\/avibactam and ceftolozane\/tazobactam","volume":"55","author":"Neves","year":"2024","journal-title":"Braz J Microbiol"},{"key":"10.1016\/j.ijid.2026.108485_bib0025","unstructured":"Avycaz. US FDA. Avycaz (ceftazidime and avibactam) for injection, for intravenous use: US prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/206494s005,s006lbl.pdf. [Accessed 18 June 2022]."},{"key":"10.1016\/j.ijid.2026.108485_bib0026","unstructured":"Zerbaxa. Us Fda. Zerbaxa (ceftolozane and tazobactam) for injection, for intravenous use: US prescribing information. 2014. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zerbaxa\/zerbaxa_pi.pdf. [Accessed 22 June 2022]."},{"issue":"10","key":"10.1016\/j.ijid.2026.108485_bib0027","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00875-17","article-title":"Multicenter evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, Respiratory tract, and wounds","volume":"61","author":"Grupper","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ijid.2026.108485_bib0028","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1128\/AAC.02969-15","article-title":"Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates","volume":"60","author":"Buehrle","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.ijid.2026.108485_bib0029","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s10096-021-04308-0","article-title":"The ERACE-PA global surveillance program: ceftolozane\/tazobactam and ceftazidime\/avibactam in vitro activity against a Global collection of carbapenem-resistant Pseudomonas aeruginosa","volume":"40","author":"Gill","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.ijid.2026.108485_bib0030","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1089\/mdr.2020.0217","article-title":"Antimicrobial activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and comparators tested against Pseudomonas aeruginosa and Klebsiella pneumoniae isolates from United States Medical Centers in 2016-2018","volume":"27","author":"Sader","year":"2021","journal-title":"Microb Drug Resist (Larchmont, NY)"},{"issue":"12","key":"10.1016\/j.ijid.2026.108485_bib0031","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1093\/jac\/dkz379","article-title":"Evaluation of in vitro activity of ceftazidime\/avibactam and ceftolozane\/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar","volume":"74","author":"Sid Ahmed","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.ijid.2026.108485_bib0032","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s15010-024-02371-1","article-title":"Ceftazidime-avibactam versus other antimicrobial agents for treatment of multidrug-resistant Pseudomonas aeruginosa: a systematic review and meta-analysis","volume":"52","author":"Gupta","year":"2024","journal-title":"Infection"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226001207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226001207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:50:40Z","timestamp":1776127840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226001207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"alternative-id":["S1201971226001207"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108485","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftazidime-avibactam versus ceftolozane-tazobactam in the treatment of drug-resistant Pseudomonas aeruginosa: a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108485"}}